Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAllergy/Clinical Immunologyeocco reslizumab (Cinqair) Coverage Prior Auth | O…
    Ask Trek AI about this page
    CurrenteoccoPolicy M-P0273

    Cinqair (reslizumab) (Intravenous) — Coverage Criteria

    Customize your policy alerts

    Sign up for eocco Policy M-P0273 alerts

    Get alerted when Policy M-P0273 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Criteria, dosing, coding, and prior authorization rules governing coverage of intravenous reslizumab (Cinqair) for members of the plan, including initial and renewal authorization requirements and concomitant therapy prohibitions.

    Policy Summary
    Payereocco
    PolicyCinqair (reslizumab) (Intravenous) — Coverage Criteria
    Policy CodePolicy M-P0273
    Change TypeNo material change
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization for reslizumab; initial approvals are valid for 12 months and may be renewed annually when renewal criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    J2786HCPCS code
    59310-0610-xxNDC
    3 mg/kg q4wDose
    12 monthsAuth length
    400/4w

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Max units
    5 coveredDiagnosis codes

    Coverage Criteria for Cinqair (reslizumab)

    Initial Approval Criteria

    Target agents will be approved when ALL of the following are met (commercial and Medicaid have different step requirements):

    Top-level: All conditions below must be met
    Prior therapy requirement: Commercial: inadequate response, contraindication, or intolerance to at least a 3-month trial of TWO of: mepolizumab, dupilumab, tezepelumab, omalizumab. Medicaid: inadequate response, contraindication, or intolerance to at least a 3-month trial of TWO of: mepolizumab, dupilumab, omalizumab.

    See policy: For Commercial Members Only (chunk 6) and For Medicaid Members Only (chunk 7).

    Continuation eligible: The requested agent is eligible for continuation of therapy: member has been treated with the requested agent (starting on samples is not approvable) within the past 90 days; OR the prescriber states the member has been treated with the requested agent (starting on samples is not approvable) within the past 90 days AND is at risk if therapy is changed.

    Agents Eligible for Continuation of Therapy (chunk 8).

    Severe eosinophilic asthma diagnostic criteria: The member has a diagnosis of severe eosinophilic asthma and BOTH of the following: (1) diagnosis confirmed while on a high‑dose inhaled corticosteroid or daily oral corticosteroid by ONE of: baseline blood eosinophils >=150 cells/microliter OR FeNO >=20 ppb OR sputum eosinophils >=2%; AND (2) evidence of uncontrolled asthma demonstrated by ONE of: >=2 systemic steroid‑treated exacerbations in past 12 months; OR >=1 serious exacerbation requiring hospitalization/ventilation/ER/urgent care in past 12 months; OR controlled asthma that worsens with tapering corticosteroids; OR baseline (pre‑therapy) FEV1 <80% predicted.

    Diagnostic thresholds and exacerbation criteria (chunk 8).

    Indication and age support: If member has an FDA‑labeled indication, age must be within FDA labeling or there must be support for use in the member's age for the indication; compendia support is acceptable.

    FDA labeling/compendia requirements (chunk 9).

    Controller therapy and adherence: For severe eosinophilic asthma: member is NOT currently treated with another asthma biologic and has been on maximally tolerated inhaled corticosteroid for >=3 months with adherence for 90 days within the past 120 days; OR member currently treated with a biologic and is on an adequately dosed inhaled corticosteroid or maximally tolerated inhaled corticosteroid for >=3 months with adherence for 90 days within the past 120 days; OR member has intolerance/hypersensitivity or FDA contraindication to inhaled corticosteroids. PLUS member is currently treated for >=3 months and adherent for 90 days within the past 120 days with one of: LABA, LAMA, LTRA, or theophylline (or has intolerance/contraindication to these agents). The member will continue asthma control therapy in combination with the requested agent.

    Controller therapy, duration, and adherence criteria (chunks 9-10).

    Biologic and inhaled steroid rules: Either: member is NOT currently treated with another asthma biologic and meets the inhaled corticosteroid treatment/adherence criteria; OR member is currently treated with a biologic and meets inhaled corticosteroid treatment/adherence criteria or has intolerance/contraindication.

    Biologic treatment options and ICS adherence (chunk 9).

    Prescriber specialty: Prescriber is a specialist in the area of the member's diagnosis (e.g., allergist, immunologist, pulmonologist) or has consulted with such a specialist.

    Prescriber specialty/consultation requirement (chunk 10).

    Concomitant immunomodulators: Member will NOT be using the requested agent in combination with another immunomodulatory agent (e.g., TNF inhibitors, JAK inhibitors, IL‑4 inhibitors); OR if using in combination, BOTH: prescribing information for the requested agent does NOT limit use with another immunomodulatory agent; AND there is supportive evidence for combination therapy (submit clinical trials, phase III studies, or guidelines).

    Concomitant therapy restrictions and evidence requirements (chunk 10).

    Contraindications: Member does NOT have any FDA‑labeled contraindications to the requested agent.

    Contraindications requirement (chunk 10).

    Renewal Criteria

    Target agents will be approved on renewal when ALL of the following are met:

    Renewal set: Member was previously approved through the plan's prior authorization process; member has demonstrated clinical benefit with the requested agent; if the diagnosis is severe eosinophilic asthma, the member has been treated within the past 90 days and is compliant with asthma control therapy (e.g., ICS, ICS/LABA, LTRA, LAMA, theophylline); the prescriber is a specialist or has consulted one; concomitant immunomodulator rules are met (see agents NOT to be used concomitantly) or supportive evidence submitted for combination use; and the member does not have any FDA‑labeled contraindications to the requested agent.

    Renewal criteria (chunk 11).

    Agents listed in the policy are designated as NOT to be used concomitantly with the requested agent unless the prescribing information allows combination use and supporting evidence is submitted. The policy provides an extensive list of specific biologics and immunomodulators that are considered contraindicated or not recommended for concomitant use, including but not limited to: Abrilada (adalimumab-afzb), Actemra (tocilizumab), Adalimumab and its biosimilars (Amjevita, Hadlima, Hulio, Humira, etc.), Anzupgo (delgocitinib), Arcalyst (rilonacept), Avsola (infliximab-axxq), Benlysta (belimumab), Bimzelx (bimekizumab-bkzx), Cibinqo (abrocitinib), Cimzia (certolizumab), Cosentyx (secukinumab), Dupixent (dupilumab), Ebglyss (lebrikizumab-lbkz), Enbrel (etanercept), Entyvio (vedolizumab), Fasenra (benralizumab), Nucala (mepolizumab), Omlyclo (omalizumab), Skyrizi (risankizumab-rzaa), Tezspire (tezepelumab-ekko), Xolair (omalizumab), and many others as listed in the policy.

    For requests to use the requested agent in combination with another immunomodulatory therapy, the policy requires BOTH that: (1) the prescribing information for the requested agent does NOT limit such combined use, and (2) the provider submits supportive evidence for combination therapy (for example, clinical trial data, phase III studies, or guideline citations). If these conditions are not met, concomitant use with agents on the list will render the request noncompliant with the policy and may result in denial.

    Medicare coverage determinations, including National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs), may apply to outpatient Part B drugs and must be followed where applicable. The policy’s guidance is intended for non-Medicare coverage determinations; when a member or claim is subject to Medicare rules, compliance with CMS manuals and any applicable NCD/LCD/LCA is required.

    Providers may search the CMS coverage database for applicable NCDs, LCDs, or LCAs at https://www.cms.gov/medicare-coverage-database/search.aspx and should apply any additional Medicare-specific instructions (including Part B billing or coverage clarifications) when Medicare is the applicable payer.

    Use of the requested agent without meeting required diagnostic and clinical criteria is considered not medically necessary. The policy requires documented confirmation of severe eosinophilic asthma by ONE of the following baseline biomarkers while on high-dose inhaled corticosteroid or daily oral corticosteroid: blood eosinophils ≥150 cells/µL, FeNO ≥20 parts per billion, or sputum eosinophils ≥2%. In addition, evidence of uncontrolled disease must be shown (for example, ≥2 steroid-treated severe exacerbations in the past 12 months, ≥1 serious exacerbation requiring hospitalization/ventilation/ER, worsening with steroid taper, or baseline FEV1 <80% predicted).

    The policy also requires that members be on and continue appropriate asthma controller therapy (e.g., inhaled corticosteroid or ICS/LABA combinations, LTRA, LAMA, theophylline) and meet prior therapy/step requirements where applicable (commercial members must document inadequate response, intolerance, or contraindication to at least two specified biologics per the plan’s step criteria; Medicaid has similar requirements). Failure to document the required controller therapy, prior biologic trials, prescriber specialty/consultation, or the diagnostic biomarker and severity criteria may lead to denial as not medically necessary.

    Billing Codes and Diagnosis Codes

    HCPCSHCPCSCovered
    J2786Injection, reslizumab, 1 mg; 1 billable unit = 1 mg
    NDCNDC
    59310-0610-xxCinqair 100 mg/10 mL single-use vial
    Covered HCPCS CodesHCPCSCovered
    J2786Injection, reslizumab, 1 mg; 1 billable unit = 1 mg
    NDCNDC
    59310-0610-xxCinqair 100 mg/10 mL single-use vial
    Covered Diagnosis Codes (ICD-10)ICD-10Covered
    J45.50Severe persistent asthma, uncomplicated
    J82.81Chronic eosinophilic pneumonia
    J82.82Acute eosinophilic pneumonia
    J82.83Eosinophilic asthma
    J82.89Other pulmonary eosinophilia, not elsewhere classified
    Baseline blood eosinophil count
    Baseline blood eosinophil count≥ 150 cells/microliter
    Fraction of exhaled nitric oxide (FeNO)
    Fraction of exhaled nitric oxide (FeNO)≥ 20 parts per billion (ppb)
    Sputum eosinophils
    Sputum eosinophils≥ 2%

    Provider Requirements, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization length and renewal

    Prior authorization is required for Cinqair. Initial approvals are valid for 12 months (365 days) and may be renewed for successive 12-month (365 day) periods when renewal criteria are met.

    Prior Authorization

    Prior authorization requirement

    Prior authorization is applied to Cinqair based on consideration of indication, safety and efficacy, and drug cost; utilization management non-quantitative treatment limitations (NQTLs) are used in the prior authorization design.

    Step Therapy

    Biologic step therapy requirement (Commercial)

    For commercial members, the member must have an inadequate response, intolerance, or contraindication to at least a three-month trial of two specified biologic agents prior to approval.

    Background and Scope

    This policy addresses use of intravenous reslizumab (Cinqair) for severe eosinophilic asthma. The diagnosis is confirmed when the member meets biomarker thresholds while on high-dose inhaled corticosteroid or daily oral corticosteroid: baseline blood eosinophil count ≥150 cells/µL, FeNO ≥20 parts per billion, or sputum eosinophils ≥2%, together with evidence of uncontrolled asthma such as frequent steroid-treated exacerbations, serious exacerbations requiring hospitalization or ER care, worsening control with steroid taper, or baseline FEV1 <80% predicted.

    Scope of the policy includes criteria for initial authorization and renewal, concomitant therapy prohibitions, required continuation rules (members treated with the agent within the past 90 days may be eligible for continuation), prior authorization requirements (initial approvals valid for 12 months and renewable for 12-month intervals), and billing/coding expectations (billing with HCPCS J2786 and NDC 59310-0610-xx for the 100 mg vial as applicable). Providers must document the diagnostic biomarkers, exacerbation history, controller therapy adherence, prior biologic use, and prescriber specialty or consultation to support medical necessity.

    Definitions and Key Identifiers

    Severe eosinophilic asthma — diagnostic thresholds
    Blood eosinophils≥ 150 cells/microliter
    FeNO≥ 20 parts per billion (ppb)
    Sputum eosinophils≥ 2%
    NDC for Cinqair
    Cinqair NDC (100 mg/10 mL single-use vial)59310-0610-xx
    Policy Summary
    Payereocco
    PolicyCinqair (reslizumab) (Intravenous) — Coverage Criteria
    Policy CodePolicy M-P0273
    Change TypeNo material change
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization for reslizumab; initial approvals are valid for 12 months and may be renewed annually when renewal criteria are met.
    SourceLink
    On This Page
    Coverage Criteria for Cinqair (reslizumab)Billing Codes and Diagnosis CodesProvider Requirements, Prior Authorization, and DocumentationBackground and ScopeDefinitions and Key Identifiers
    • Required trials: two of mepolizumab (Nucala), dupilumab (Dupixent), tezepelumab (Tezspire), or omalizumab (Xolair).
    • Each trial must be at least three (3) months.
    Note

    Step therapy not specified in NQTL checklist

    The NQTL checklist documents that prior authorization was considered for this agent but does not specify step therapy sequences within the checklist section of the policy.

    Documentation Required

    Clinical documentation to support medical necessity

    Include clinical documentation to support medical necessity: baseline biomarker results, exacerbation history, spirometry (FEV1), medication adherence, and documentation of prior biologic and controller therapy trials.

    • Baseline biomarker: blood eosinophil count, FeNO, or sputum eosinophils (see thresholds).
    • History of uncontrolled asthma/exacerbations (e.g., ≥2 steroid-treated exacerbations in past 12 months or ≥1 serious exacerbation).
    • Baseline (prior to therapy) FEV1 value.
    • Medication history showing use/adherence to controller therapy and prior biologic use (excluding samples).
    Billing Rule

    Required coding and diagnosis documentation

    Bill using HCPCS J2786 (reslizumab, 1 mg). When relevant, document the product NDC 59310-0610-xx for the Cinqair 100 mg/10 mL vial and include an applicable ICD-10 diagnosis from the covered list.

    • HCPCS: J2786 - Injection, reslizumab, 1 mg; 1 billable unit = 1 mg.
    • NDC: Cinqair 100 mg/10 mL single-use vial — 59310-0610-xx.
    • Include an applicable diagnosis code from Appendix 1 (e.g., J45.50, J82.81–J82.89).
    Denial Risk

    Prior biologic therapy required — denial risk

    Failure to document required prior biologic therapy trials as specified (commercial: two agents including mepolizumab, dupilumab, tezepelumab, or omalizumab for ≥3 months each) may result in denial of coverage.

    • Commercial requirement: two biologic agents tried for at least three months each (see policy for allowed agents).
    • Medicaid lists a similar two-agent requirement (mepolizumab, dupilumab, or omalizumab).
    Denial Risk

    Diagnostic and severity confirmation required — denial risk

    Lack of documented diagnostic confirmation of severe eosinophilic asthma (baseline eosinophils ≥150 cells/µL, FeNO ≥20 ppb, or sputum eosinophils ≥2%) or failure to document severity/exacerbation history or FEV1 may lead to denial.

    • Diagnostic thresholds: blood eosinophils ≥150 cells/µL; FeNO ≥20 ppb; or sputum eosinophils ≥2% (measured while on high-dose ICS or daily oral corticosteroid).
    • Severity evidence: ≥2 steroid-treated exacerbations in past 12 months, ≥1 serious exacerbation requiring hospitalization/ventilation/ER, worsening with steroid taper, or baseline FEV1 <80% predicted.
    Note

    Prior authorization drivers (NQTL factors)

    Prior authorization may be applied due to indication considerations, safety and efficacy concerns, and the cost of the drug as noted in the NQTL factor checklist.

    • NQTL checklist conclusions marked 'Consider for PA' for indication, safety and efficacy, and cost.